KRAS突变与肿瘤代谢重编程的研究进展

Research Progress of KRAS Mutation and Tumor Metabolic Reprogramming

KRAS基因是最常见的致癌突变基因,其获得性突变发生在约30%的人类癌症中,通常与预后不良和耐药性有关。尽管KRAS在恶性肿瘤中的重要性已广为人知,但目前还没有选择性抑制剂被批准用于KRAS突变肿瘤的治疗。最近的研究发现KRAS突变能够促进代谢重编程,从而产生维持肿瘤细胞不受限制的增殖所必需的营养物质,因此靶向代谢重编程的方法也为肿瘤治疗提供了新方向。综述KRAS突变所导致的代谢重编程在肿瘤中的最新发现,并总结相关的潜在治疗靶点。

KRAS is one of the best-known proto-oncogenes.Its gain-of-function mutations occur in approximately 30%of all human cancers and are commonly associated with poor prognosis and therapeutic resistance.Despite its well-recognized importance in cancer malignancy,no selective inhibitors have been approved for KRAS mutant cancer treatment.Recent studies have shown that KRAS mutation promotes a metabolic reprogramming of tumor cells to produce essential nutrients to support unconstrained proliferation,therefore,targeting metabolic reprogramming also provides a new direction for tumor therapy.This article reviews the latest metabolic reprogramming caused by KRAS mutation in tumors with a summary of related potential therapeutic targets.